Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data.
Eur J Clin Pharmacol. 2024 Jun;80(6):797-812. doi: 10.1007/s00228-024-03648-y. Epub 2024 Mar 2.
Eur J Clin Pharmacol. 2024.
PMID: 38430266
Review.
Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, Taxis K, Borgsteede SD.
Weersink RA, et al. Among authors: monster simons mh.
Drug Saf. 2018 Jun;41(6):603-613. doi: 10.1007/s40264-017-0635-x.
Drug Saf. 2018.
PMID: 29330714
Free PMC article.
Review.
Item in Clipboard
Safe use of proton pump inhibitors in patients with cirrhosis.
Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, van Putten SAW, Taxis K, Borgsteede SD.
Weersink RA, et al. Among authors: monster simons mh.
Br J Clin Pharmacol. 2018 Aug;84(8):1806-1820. doi: 10.1111/bcp.13615. Epub 2018 Jun 7.
Br J Clin Pharmacol. 2018.
PMID: 29688583
Free PMC article.
Item in Clipboard
Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.
Weersink RA, Bouma M, Burger DM, Drenth JP, Hunfeld NG, Kranenborg M, Monster-Simons MH, van Putten SA, Metselaar HJ, Taxis K, Borgsteede SD.
Weersink RA, et al. Among authors: monster simons mh.
BMJ Open. 2016 Oct 12;6(10):e012991. doi: 10.1136/bmjopen-2016-012991.
BMJ Open. 2016.
PMID: 27733414
Free PMC article.
Review.
Item in Clipboard
Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.
Weersink RA, Timmermans L, Monster-Simons MH, Mol PGM, Metselaar HJ, Borgsteede SD, Taxis K.
Weersink RA, et al. Among authors: monster simons mh.
Front Pharmacol. 2019 Sep 17;10:1031. doi: 10.3389/fphar.2019.01031. eCollection 2019.
Front Pharmacol. 2019.
PMID: 31607904
Free PMC article.
Item in Clipboard
A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe.
Koomen JV, Stevens J, Monster-Simons MH, Heerspink HJL, Mol PGM.
Koomen JV, et al. Among authors: monster simons mh.
Front Pharmacol. 2021 Apr 28;12:626766. doi: 10.3389/fphar.2021.626766. eCollection 2021.
Front Pharmacol. 2021.
PMID: 33995023
Free PMC article.
Item in Clipboard
Reported adverse drug reactions and their determinants in Dutch children outside the hospital.
Schirm E, Tobi H, van Puijenbroek EP, Monster-Simons MH, de Jong-van den Berg LT.
Schirm E, et al. Among authors: monster simons mh.
Pharmacoepidemiol Drug Saf. 2004 Mar;13(3):159-65. doi: 10.1002/pds.843.
Pharmacoepidemiol Drug Saf. 2004.
PMID: 15072115
Item in Clipboard
Cite
Cite